ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2019
Association of Epigenetic Clock with Consensus Molecular Subtypes and Overall Survival of Colorectal Cancer.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival.International journal of cancer · 2026Article
- Single-cell epigenomics of colorectal cancer.Experimental & molecular medicine · 2026Review
- Distinct epigenetic aging in sporadic and hereditary neuroendocrine neoplasms.Clinical epigenetics · 2026Article
- Abnormal epigenetic aging of epigenetic outliers in normal colon mucosa from colorectal cancer patients.Scientific reports · 2026Article
- Accelerating epigenetic age in right-sided colon cancer predicts a favorable outcome.Clinical epigenetics · 2025Article
- The relationship between epigenetic biomarkers and the risk of diabetes and cancer: a machine learning modeling approach.Frontiers in public health · 2025Article
- From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer.Current treatment options in oncology · 2024Review
- Blood-Based Epigenetic Age Acceleration and Incident Colorectal Cancer Risk: Findings from a Population-Based Case-Control Study.International journal of molecular sciences · 2024Article
- Global metabolomics revealed deviations from the metabolic aging clock in colorectal cancer patients.Theranostics · 2024Article
- Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management.Cancers · 2023Review
- Open access-enabled evaluation of epigenetic age acceleration in colorectal cancer and development of a classifier with diagnostic potential.Frontiers in genetics · 2023Article
- High DNA methylation age deceleration defines an aggressive phenotype with immunoexclusion environments in endometrial carcinoma.Frontiers in immunology · 2023Article
- Redefining Age-Based Screening and Diagnostic Guidelines: An Opportunity for Biological Aging Clocks in Clinical Medicine?The lancet. Healthy longevity · 2022Article
- Obesity-Associated Differentially Methylated Regions in Colon Cancer.Journal of personalized medicine · 2022Article
- Genes and Longevity of Lifespan.International journal of molecular sciences · 2022Review
- DNA Methylation, Aging, and Cancer Risk: A Mini-Review.Frontiers in bioinformatics · 2022Review
- Epigenetic Age Acceleration Is Not Associated with Age-Related Macular Degeneration.International journal of molecular sciences · 2021Article
- Article
- Article
- The use of DNA methylation clock in aging research.Experimental biology and medicine (Maywood, N.J.) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundEpigenetic clock, or DNA methylation age, has been shown to highly correlate with chronologic age. Epigenetic age acceleration, the difference between DNA methylation age and individual's chronologic age, was observed in colorectal cancer. However, the association of epigenetic age acceleration with colorectal cancer tumor molecular characteristics, clinical characteristics, and patient outcomes has not been systematically investigated.
methodsDNA methylation ages of 345 patients with colorectal cancer from The Cancer Genome Atlas (TCGA) were computed using the Horvath age prediction model. Multivariate linear regression was used to assess the association of epigenetic age acceleration with molecular and clinical features of colorectal cancer, including consensus molecular subtypes (CMS1-CMS4) and tumor stage Cox proportional hazards regression was used to assess the association of epigenetic age acceleration with survival.
resultsEpigenetic age acceleration is significantly associated with CMS. Compared with CMS2, epigenetic age acceleration for CMS1, CMS3, and CMS4 was 23.90 years [
conclusionsEpigenetic age acceleration is associated with colorectal cancer tumor molecular characteristics, and a significant predictor of overall survival of colorectal cancer, along with age and tumor stage. IMPACT: Combining information of colonic tissue epigenetic age acceleration and tumor molecular characteristics may improve prognosis prediction in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.